Nuvation Bio's Ibtrozi Gains FDA Approval, Paving Way for Lung Cancer Competition
Nuvation Bio's Ibtrozi (taletrectinib) has received FDA approval to treat ROS1-positive NSCLC, challenging existing drugs from Pfizer, BMS, and Roche, with potential for significant market impact due to its efficacy, safety profile, and the recent change in treatment guidelines.